Analysis of prognostic factors and treatment modes of patients with recurrent endometrial carcinoma
Evidence-based Complementary and Alternative Medicine — Li Y, Yang D, Yang S, et al. | October 20, 2021
As recurrent endometrial cancer (REC) is often linked with a poor prognosis, researchers herein sought the risk factors affecting REC prognosis and investigated appropriate treatment modalities to improve the prognosis and treatment strategies for patients with REC.
A total of 100 patients with REC were included in this study.
Thirty patients had a poor prognosis and 70 had a good prognosis after 3 years of follow-up.
Multifactorial analysis revealed the following as independent factors affecting poor prognosis in REC patients: TFI and treatment modality after recurrence.
The 3-year OS was 74.00% and 3-year PFS was 70.00% for REC patients.
Lower levels of 3-year OS and 3-year PFS were recorded for patients whose DFI was less than 12 months or treated with palliative chemotherapy (PC) after relapse.
An improvement in the prognosis of REC patients is obvious in correlation with providing definitive local therapy (DLT).
For cases who can only select PC, chemoradiotherapy and DFI after primary surgery are valuable to prognosticate the chemotherapy effect, and the first choice should be the combination of paclitaxel and platinum drugs for chemotherapy.